|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CLPX |
Gene summary for CLPX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CLPX | Gene ID | 10845 |
| Gene name | caseinolytic mitochondrial matrix peptidase chaperone subunit X | |
| Gene Alias | EPP2 | |
| Cytomap | 15q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0006457 | UniProtAcc | A0A024R5X7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10845 | CLPX | LZE4T | Human | Esophagus | ESCC | 3.62e-09 | 3.13e-01 | 0.0811 |
| 10845 | CLPX | LZE7T | Human | Esophagus | ESCC | 6.10e-06 | 4.48e-01 | 0.0667 |
| 10845 | CLPX | LZE22T | Human | Esophagus | ESCC | 1.39e-02 | 2.33e-01 | 0.068 |
| 10845 | CLPX | LZE24T | Human | Esophagus | ESCC | 1.75e-08 | 1.89e-01 | 0.0596 |
| 10845 | CLPX | P2T-E | Human | Esophagus | ESCC | 1.39e-25 | 4.06e-01 | 0.1177 |
| 10845 | CLPX | P4T-E | Human | Esophagus | ESCC | 3.03e-20 | 3.79e-01 | 0.1323 |
| 10845 | CLPX | P5T-E | Human | Esophagus | ESCC | 6.01e-11 | 2.82e-01 | 0.1327 |
| 10845 | CLPX | P8T-E | Human | Esophagus | ESCC | 1.30e-20 | 3.01e-01 | 0.0889 |
| 10845 | CLPX | P9T-E | Human | Esophagus | ESCC | 2.98e-14 | 2.42e-01 | 0.1131 |
| 10845 | CLPX | P10T-E | Human | Esophagus | ESCC | 7.00e-27 | 4.10e-01 | 0.116 |
| 10845 | CLPX | P11T-E | Human | Esophagus | ESCC | 1.84e-04 | 3.51e-01 | 0.1426 |
| 10845 | CLPX | P12T-E | Human | Esophagus | ESCC | 1.63e-30 | 5.48e-01 | 0.1122 |
| 10845 | CLPX | P15T-E | Human | Esophagus | ESCC | 4.73e-23 | 4.59e-01 | 0.1149 |
| 10845 | CLPX | P16T-E | Human | Esophagus | ESCC | 1.15e-28 | 5.81e-01 | 0.1153 |
| 10845 | CLPX | P19T-E | Human | Esophagus | ESCC | 2.59e-07 | 3.32e-01 | 0.1662 |
| 10845 | CLPX | P20T-E | Human | Esophagus | ESCC | 1.42e-10 | 1.42e-01 | 0.1124 |
| 10845 | CLPX | P21T-E | Human | Esophagus | ESCC | 1.18e-07 | 1.90e-01 | 0.1617 |
| 10845 | CLPX | P22T-E | Human | Esophagus | ESCC | 6.81e-12 | 2.73e-01 | 0.1236 |
| 10845 | CLPX | P23T-E | Human | Esophagus | ESCC | 1.16e-12 | 5.18e-01 | 0.108 |
| 10845 | CLPX | P24T-E | Human | Esophagus | ESCC | 1.81e-12 | 2.70e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
| GO:0046034111 | Esophagus | ESCC | ATP metabolic process | 189/8552 | 277/18723 | 1.99e-14 | 1.04e-12 | 189 |
| GO:0010952111 | Esophagus | ESCC | positive regulation of peptidase activity | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
| GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
| GO:00458627 | Liver | NAFLD | positive regulation of proteolysis | 65/1882 | 372/18723 | 6.58e-06 | 2.29e-04 | 65 |
| GO:00525477 | Liver | NAFLD | regulation of peptidase activity | 72/1882 | 461/18723 | 1.03e-04 | 2.03e-03 | 72 |
| GO:00460347 | Liver | NAFLD | ATP metabolic process | 46/1882 | 277/18723 | 4.55e-04 | 6.69e-03 | 46 |
| GO:004603422 | Liver | HCC | ATP metabolic process | 198/7958 | 277/18723 | 8.30e-23 | 1.55e-20 | 198 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:004586222 | Liver | HCC | positive regulation of proteolysis | 232/7958 | 372/18723 | 5.66e-15 | 3.98e-13 | 232 |
| GO:005254722 | Liver | HCC | regulation of peptidase activity | 247/7958 | 461/18723 | 8.28e-07 | 1.27e-05 | 247 |
| GO:001095212 | Liver | HCC | positive regulation of peptidase activity | 110/7958 | 197/18723 | 1.04e-04 | 8.98e-04 | 110 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:004586220 | Oral cavity | OSCC | positive regulation of proteolysis | 236/7305 | 372/18723 | 6.53e-22 | 1.38e-19 | 236 |
| GO:005254720 | Oral cavity | OSCC | regulation of peptidase activity | 255/7305 | 461/18723 | 5.78e-13 | 2.75e-11 | 255 |
| GO:004603420 | Oral cavity | OSCC | ATP metabolic process | 166/7305 | 277/18723 | 1.16e-12 | 5.12e-11 | 166 |
| GO:001095220 | Oral cavity | OSCC | positive regulation of peptidase activity | 123/7305 | 197/18723 | 2.12e-11 | 7.21e-10 | 123 |
| GO:0006457111 | Skin | cSCC | protein folding | 131/4864 | 212/18723 | 2.96e-28 | 1.32e-25 | 131 |
| GO:0046034112 | Skin | cSCC | ATP metabolic process | 142/4864 | 277/18723 | 1.38e-19 | 1.96e-17 | 142 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CLPX | SNV | Missense_Mutation | c.839A>T | p.Asp280Val | p.D280V | O76031 | protein_coding | tolerated(0.23) | benign(0.011) | TCGA-A8-A06Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| CLPX | SNV | Missense_Mutation | novel | c.1075G>A | p.Glu359Lys | p.E359K | O76031 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| CLPX | SNV | Missense_Mutation | c.599N>C | p.Arg200Thr | p.R200T | O76031 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CLPX | SNV | Missense_Mutation | c.278N>G | p.Ser93Cys | p.S93C | O76031 | protein_coding | deleterious(0.01) | possibly_damaging(0.478) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| CLPX | insertion | Nonsense_Mutation | novel | c.524_525insGATAGGGCCAGAGATAGTAAGGTGTATC | p.Tyr175Ter | p.Y175* | O76031 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CLPX | insertion | Frame_Shift_Ins | rs747704551 | c.1721_1722insCAAACCAATAA | p.Glu574AspfsTer24 | p.E574Dfs*24 | O76031 | protein_coding | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | ||
| CLPX | SNV | Missense_Mutation | c.23N>A | p.Thr8Asn | p.T8N | O76031 | protein_coding | tolerated_low_confidence(0.13) | benign(0.059) | TCGA-A6-A566-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | PD | |
| CLPX | SNV | Missense_Mutation | rs771233943 | c.1429C>T | p.Arg477Trp | p.R477W | O76031 | protein_coding | deleterious(0.03) | probably_damaging(0.964) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CLPX | SNV | Missense_Mutation | c.1091G>A | p.Gly364Asp | p.G364D | O76031 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| CLPX | SNV | Missense_Mutation | rs771233943 | c.1429N>T | p.Arg477Trp | p.R477W | O76031 | protein_coding | deleterious(0.03) | probably_damaging(0.964) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |